Truist Securities Maintains Hold on Quest Diagnostics, Lowers Price Target to $145-Report Released on 1 February 2024
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald maintains a Hold rating on Quest Diagnostics (NYSE:DGX) and lowers the price target from $150 to $145 as of 1 February 2024.

February 02, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities maintains a Hold rating on Quest Diagnostics and lowers the price target from $150 to $145.
The reduction in the price target by Truist Securities suggests a less optimistic outlook on Quest Diagnostics' stock value in the short term. This adjustment could lead to a negative perception among investors, potentially causing a decrease in the stock price. The Hold rating indicates that the analyst does not see significant upside or downside in the near term, but the lowering of the price target is a bearish signal.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100